LCZ696 effect on improving quality of life and ejection fraction of palestinian patients with heart failure and reduced ejection fraction

Abstract EN

Objective: With the LCZ696 (sacubutril/valsartan) being a new add-on treatment to patients with congestive heart failure and reduced ejection fraction, this study aims to show the effects of LCZ696 on ejection fraction (first reported) and the quality of life of the Palestinian population with heart failure.

Methods: The first 102 patients who were started on this medication were examined.

In addition, all demographic data were tabulated, and all follow-up visits were analyzed.

The quality of life based on the New York Heart Association (NYHA) classification was recorded.

All hospital admissions, deaths, labs, and echocardiograms were recorded.

The length of study was 6–12 months (mean of nine months), and all patients, signed an informed consent form allowing for their charts to be reviewed.

Results: The LCZ696 has been studied for over a period of 6–12 months on 102 patients with heart failure and reduced ejection fraction.

Measurement of ejection fraction was measured by standard protocol before, during, and after initiating LCZ696.

Records showed a significant improvement in the left ventricular EF and in their NYHA classification of heart failure.

Conclusion: Despite its limitations, we think that LCZ696 (sacubutril/valsartan) has a very promising outcome on the quality of life and the ejection fraction of a group of patients with congestive heart failure and reduced ejection fraction.

There were statistical improvements on the quality of life as well as in the ejection fraction (first reported) with an acceptable safety margin.

However, such effect needs to be replicated in other prospective and retrospective studies